Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients

被引：266

作者：

Byrski, T. ^{[1
]}

Huzarski, T. ^{[2
]}

Dent, R. ^{[3
]}

Marczyk, E. ^{[4
]}

Jasiowka, M. ^{[4
]}

Gronwald, J. ^{[2
]}

Jakubowicz, J. ^{[4
]}

Cybulski, C. ^{[2
]}

Wisniowski, R. ^{[5
]}

Godlewski, D. ^{[6
]}

Lubinski, J. ^{[2
]}

Narod, S. A. ^{[7
]}

机构：

[1] Pomeranian Med Univ, Dept Oncol, Int Hereditary Canc Ctr, Szczecin, Poland

[2] Pomeranian Med Univ, Dept Genet & Pathol, Int Hereditary Canc Ctr, Szczecin, Poland

[3] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada

[4] Inst Oncol, Krakow, Poland

[5] Reg Oncol Ctr, Bielsko Biala, Poland

[6] Ctr Epidemiol & Prevent, Poznan, Poland

[7] Womens Coll Res Inst, Toronto, ON M5G 1N8, Canada

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2014年 / 147卷 / 02期

关键词：

BRCA1; Breast cancer; Neoadjuvant cisplatin; BRCA2; MUTATIONS; CHEMOTHERAPY; SURVIVAL; PACLITAXEL; CARRIERS; AGE;

D O I：

10.1007/s10549-014-3100-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The aim of this study is to estimate the frequency of pathologic complete response (pCR) after neoadjuvant treatment with cisplatin chemotherapy in women with breast cancer and a BRCA1 mutation. One hundred and seven women with breast cancer and a BRCA1 mutation, who were diagnosed with stage I to III breast cancer between December 2006 and June 2014, were treated with cisplatin 75 mg/m(2) every 3 weeks for four cycles, followed by mastectomy and conventional chemotherapy. Information was collected on clinical stage, grade, hormone receptor status, and Her2neu status prior to treatment. pCR was determined by review of surgical specimens. One hundred and seven patients were enrolled in the study, including 93 patients who were treated for first primary breast cancer and 14 patients who had previously received treatment for a prior cancer. A pCR was observed in 65 of the 107 patients (61 %). Platinum-based chemotherapy is effective in a high proportion of patients with BRCA1-associated breast cancer.

引用

页码：401 / 405

页数：5

共 21 条

[1]

The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin [J].

Bhattacharyya, A ;

Ear, US ;

Koller, BH ;

Weichselbaum, RR ;

Bishop, DK .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (31) :23899-23903

[2]

Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy [J].

Byrski, Tomasz ;

Gronwald, Jacek ;

Huzarski, Tomasz ;

Grzybowska, Ewa ;

Budryk, Magdalena ;

Stawicka, Malgorzata ;

Mierzwa, Tomasz ;

Szwiec, Marek ;

Wisniowski, Rafal ;

Siolek, Monika ;

Dent, Rebecca ;

Lubinski, Jan ;

Narod, Steven .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) :375-379

[3]

BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance [J].

Chabalier, C. ;

Lamare, C. ;

Racca, C. ;

Privat, M. ;

Valette, A. ;

Larminat, F. .

CELL CYCLE, 2006, 5 (09) :1001-1007

[4]

Estrogen receptor status in BRCA1- and BRCA2-related breast cancer:: The influence of age, grade, and histological type [J].

Foulkes, WD ;

Metcalfe, K ;

Sun, P ;

Hanna, WM ;

Lynch, HT ;

Ghadirian, P ;

Tung, N ;

Olopade, OI ;

Weber, BL ;

McLennan, J ;

Olivotto, IA ;

Bégin, LR ;

Narod, SA .

CLINICAL CANCER RESEARCH, 2004, 10 (06) :2029-2034

[5]

A high proportion of founder BRCA1 mutations in Polish breast cancer families [J].

Górski, B ;

Jakubowska, A ;

Huzarski, T ;

Byrski, T ;

Gronwald, J ;

Grzybowska, E ;

Mackiewicz, A ;

Stawicka, M ;

Bebenek, M ;

Sorokin, D ;

Fiszer-Maliszewska, L ;

Haus, O ;

Janiszewska, H ;

Niepsuj, S ;

Gózdz, S ;

Zaremba, L ;

Posmyk, M ;

Pluzanska, M ;

Kilar, E ;

Czudowska, D ;

Wasko, B ;

Miturski, R ;

Kowalczyk, JR ;

Urbanski, K ;

Szwiec, M ;

Koc, J ;

Debniak, B ;

Rozmiarek, A ;

Debniak, T ;

Cybulski, C ;

Kowalska, E ;

Toloczko-Grabarek, A ;

Zajaczek, S ;

Menkiszak, J ;

Medrek, K ;

Masojc, B ;

Mierzejewski, M ;

Narod, SA ;

Lubinski, J .

INTERNATIONAL JOURNAL OF CANCER, 2004, 110 (05) :683-686

[6]

Ten-Year Survival in Patients With BRCA1-Negative and BRCA1-Positive Breast Cancer [J].

Huzarski, Tomasz ;

Byrski, Tomasz ;

Gronwald, Jacek ;

Gorski, Bohdan ;

Domagala, Pawel ;

Cybulski, Cezary ;

Oszurek, Oleg ;

Szwiec, Marek ;

Gugala, Karol ;

Stawicka, Malgorzata ;

Morawiec, Zbigniew ;

Mierzwa, Tomasz ;

Janiszewska, Hanna ;

Kilar, Ewa ;

Marczyk, Elzbieta ;

Kozak-Klonowska, Beata ;

Siolek, Monika ;

Surdyka, Dariusz ;

Wisniowski, Rafal ;

Posmyk, Michal ;

Sun, Ping ;

Lubinski, Jan ;

Narod, Steven A. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) :3191-+

[7]

The role of BRCA1 in the cellular response to chemotherapy [J].

Kennedy, RD ;

Quinn, JE ;

Mullan, PB ;

Johnston, PG ;

Harkin, DP .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (22) :1659-1668

[8]

Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations [J].

Lakhani, SR ;

Jacquemier, J ;

Sloane, JP ;

Gusterson, BA ;

Anderson, TJ ;

van de Vijver, MJ ;

Farid, LM ;

Venter, D ;

Antoniou, A ;

Storfer-Isser, A ;

Smyth, E ;

Steel, CM ;

Haites, N ;

Scott, RJ ;

Goldgar, D ;

Neuhausen, S ;

Daly, PA ;

Ormiston, W ;

McManus, R ;

Scherneck, S ;

Ponder, BAJ ;

Ford, D ;

Peto, J ;

Stoppa-Lyonnet, D ;

Bignon, YJ ;

Struewing, JP ;

Spurr, NK ;

Bishop, DT ;

Klijn, JGM ;

Devilee, P ;

Cornelisse, CJ ;

Lasset, C ;

Lenoir, G ;

Barkardottir, RB ;

Egilsson, V ;

Hamann, U ;

Chang-Claude, J ;

Sobol, H ;

Weber, B ;

Stratton, MR ;

Easton, DF .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (15) :1138-1145

[9]

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer [J].

Liedtke, Cornelia ;

Mazouni, Chafika ;

Hess, Kenneth R. ;

Andre, Fabrice ;

Tordai, Attila ;

Mejia, Jaime A. ;

Symmans, W. Fraser ;

Gonzalez-Angulo, Ana M. ;

Hennessy, Bryan ;

Green, Marjorie ;

Cristofanilli, Massimo ;

Hortobagyi, Gabriel N. ;

Pusztai, Lajos .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (08) :1275-1281

[10]

Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers [J].

Mazouni, C. ;

Kau, S.-W. ;

Frye, D. ;

Andre, F. ;

Kuerer, H. M. ;

Buchholz, T. A. ;

Symmans, W. F. ;

Anderson, K. ;

Hess, K. R. ;

Gonzalez-Angulo, A. M. ;

Hortobagyi, G. N. ;

Buzdar, A. U. ;

Pusztai, L. .

ANNALS OF ONCOLOGY, 2007, 18 (05) :874-880

← 1 2 3 →